uniQure Stock Falls Despite FDA Priority Review for Huntington’s Gene Therapy
uniQure's stock dropped 3% despite the FDA granting priority review for its Huntington's disease gene therapy, AMT-130.
uniQure's stock dropped 3% despite the FDA granting priority review for its Huntington's disease gene therapy, AMT-130. This is an original TLT brief based on reporting by Blockonomi, with live market data added, as of Mon, 02 Nov 2026 19:30:04 UTC.
The FDA's priority review for AMT-130 highlights the potential for a new treatment for Huntington's disease, a devastating neurodegenerative disorder. However, the stock's decline suggests investor uncertainty about the therapy's commercial prospects or potential risks.
- FDA grants priority review to uniQure's Huntington's gene therapy, AMT-130.
- Decision expected by May 1, 2027.
- uniQure plans to screen 200 patients for confirmatory trial by year-end.
- QURE stock falls 3% to $24.09, breaking below $24.83 support.
- PayPal Stock Falls Despite Earnings Beat Amid Revenue Growth Slowdown
- uniQure Stock Falls Despite FDA Priority Review for Huntington’s Gene Therapy — this brief
The U.S. Food and Drug Administration (FDA) has granted priority review to uniQure's gene therapy, AMT-130, for the treatment of Huntington's disease. This decision underscores the potential of AMT-130 to address a critical unmet need in treating this debilitating neurodegenerative disorder.
The FDA has set a target action date of May 1, 2027, for its decision on AMT-130. In preparation, uniQure intends to initiate the screening of 200 patients for its confirmatory trial by the end of 2023. AMT-130 utilizes uniQure's proprietary gene-silencing platform to target the underlying genetic cause of Huntington's disease.
Despite the positive regulatory news, uniQure's stock fell by 3% to $24.09, as reported by both Blockonomi and CoinCodex. This decline suggests that investors may be cautious about the therapy's commercial potential or possible risks, despite the promising regulatory advancement.
The stock's drop also broke below the $24.83 support level, as noted by Blockonomi, indicating potential further downside if the bearish sentiment continues. This comes amidst a broader market downturn, with the total crypto market cap at $2.65 trillion and 
Bitcoin down 1.07% over the past 24 hours.
In contrast, Rivian (RIVN) saw its stock rise over 3% after UBS upgraded the stock to Buy with a $17 price target, citing stronger sales, demand for the R2 model, and improving profit margins, as reported by CoinCodex.
1 key figure independently matched across 2 outlets reporting this story.
TLT extracts the figures each outlet reports and flags the ones that agree. Numbers cited by only one outlet are attributed in the brief, not shown as corroborated.
uniQure Stock Falls Despite FDA Priority Review for Huntingt — questions & answers
What is the FDA's target decision date for AMT-130?
The FDA plans to make a decision on AMT-130 by May 1, 2027.
How many patients will uniQure screen for its confirmatory trial?
uniQure plans to screen 200 patients for its confirmatory trial by the end of 2023.
Why did uniQure's stock fall despite the FDA's priority review?
The stock may have fallen due to investor uncertainty about the therapy's commercial prospects or potential risks.
Which outlets reported this story?
This is an original TLT brief that synthesises reporting from Blockonomi. It is not a copy of any one article — follow the source links above for the original reporting.
Original summary — not financial advice. This is an original TLT brief that summarises a development reported elsewhere and adds live market data for context; it is not the original article and reproduces no part of it. Follow the source link above for full details. Crypto is volatile and high-risk — always do your own research.